Boehringer Ingelheim has announced the launch of three Phase III clinical trials aimed at advancing precision oncology for patients with some of the most aggressive forms of cancer. The new studies focus on small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (epNEC), and HER2-mutant non-small cell lung cancer (NSCLC), reflecting the company’s strategy to expand biomarker-driven therapies into earlier stages of treatment while addressing areas of significant unmet medical need.
The latest additions to Boehringer’s oncology pipeline include the DAREON®-Lung-1 and DAREON®-NEC-1 trials evaluating the investigational therapy obrixtamig, as well as the Beamion LUNG-3 trial studying zongertinib in patients with early-stage HER2-mutant NSCLC.
According to the company, the new studies are designed to strengthen the role of precision medicine by matching targeted therapies with specific tumor biomarkers. This approach seeks to improve treatment outcomes by identifying patients who are most likely to benefit from specialized therapies.
“People living with aggressive cancers often face a shortage of treatment choices,” said Lykke Hinsch Gylvin, MD, Chief Medical Officer at Boehringer Ingelheim. She noted that the new clinical trials represent an important step in moving targeted therapies into earlier treatment settings while expanding biomarker-informed treatment strategies for patients with difficult-to-treat cancers.
The DAREON clinical program focuses on obrixtamig, an investigational bispecific T-cell engager that targets Delta-like canonical Notch ligand 3 (DLL3), a protein commonly found on tumor cells in SCLC and epNEC but largely absent from healthy tissue. Researchers believe this characteristic makes DLL3 a promising biomarker for identifying patients who may benefit from targeted immunotherapy.
Small cell lung cancer remains one of the most aggressive forms of lung cancer, with many patients experiencing rapid disease progression and limited long-term benefit from currently available treatments. Similarly, extrapulmonary neuroendocrine carcinoma is a rare and highly aggressive cancer for which therapeutic advances have remained limited over the past several decades.
The Phase III DAREON®-Lung-1 trial will investigate whether adding obrixtamig to the current first-line treatment regimen of atezolizumab and chemotherapy can improve outcomes in patients with extensive-stage SCLC. Meanwhile, the DAREON®-NEC-1 study will evaluate obrixtamig in combination with carboplatin and etoposide as first-line therapy for patients with DLL3-positive unresectable or metastatic epNEC.
By incorporating biomarker testing into patient selection, Boehringer hopes these studies will help establish a more personalized treatment approach for aggressive neuroendocrine cancers.
The company’s third Phase III study, Beamion LUNG-3, shifts the focus toward earlier intervention in HER2 (ERBB2)-mutant non-small cell lung cancer. The global randomized trial will assess zongertinib as an adjuvant treatment following surgery in patients with stage II to IIIB HER2-mutant NSCLC who have already received either neoadjuvant or adjuvant therapy.
The study aims to determine whether zongertinib can extend disease-free survival after complete surgical resection, addressing the substantial risk of cancer recurrence even after curative-intent treatment. If successful, the trial could help establish a targeted postoperative treatment option for patients with HER2-driven lung cancer, an area where few targeted adjuvant therapies currently exist.
Zongertinib is an irreversible tyrosine kinase inhibitor designed to selectively target HER2 while minimizing effects on normal EGFR activity, potentially reducing treatment-related side effects. The therapy has already received approval in the United States, China, Hong Kong, and Japan for adults with advanced HER2-mutant NSCLC and continues to be evaluated across multiple stages of lung cancer.
Beyond these individual studies, Boehringer Ingelheim says the expanded clinical program reflects its broader commitment to precision oncology. The company continues to invest in therapies that combine biomarker-guided targeted treatments with innovative immunotherapy approaches, including next-generation T-cell engagers, cancer vaccines, and exploratory oncolytic virus technologies.
Obrixtamig itself is being developed through a long-term collaboration with Oxford BioTherapeutics, leveraging the company’s technology platform to identify novel cancer targets for immunotherapy development.
With the launch of these three Phase III trials, Boehringer Ingelheim is reinforcing its focus on bringing more personalized treatment options to patients with aggressive cancers, while exploring ways to improve long-term survival through earlier intervention and biomarker-driven care.